Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MACK $5.54 0.4200 +8.20%
VRML $1.11 0.0700 +6.73%
TGTX $6.41 0.3500 +5.78%
ARQL $1.50 0.0800 +5.63%
TKMR $3.25 0.1700 +5.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $0.47 -0.0706 -13.11%
GALE $0.28 -0.0261 -8.45%
FATE $2.39 -0.1150 -4.60%
ZIOP $5.55 -0.2500 -4.31%
ARIA $10.38 -0.4000 -3.71%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress

(Amgen) Oct 5, 2016 - Interim data from Phase 2 trial provides further insight into Imlygic® (talimogene laherparepvec) as a potential combination partner with a checkpoint inhibitor for patients with advanced melanoma: retrospective analyses of key studies evaluating Vectibix® (panitumumab) combination regimen in first- and second-line metastatic colorectal cancer evaluate impact of tumor site of origin on treatment efficacy.
read corporate press release 

ESMO 2016 Press Release: Improving Cancer Screening Participation Should be a Priority

(ESMO) Oct 6, 2016 - Early diagnosis of cancer is linked to better survival rates. Unfortunately, participation rates for cancer screening worldwide are low even when screening programmes are free. The ESMO 2016 Congress is showcasing five studies on this important area of cancer management which look at alternative ways to overcome barriers and improve screening rates.
read press release 

Less Regular Cervical Screening Could Benefit Women, Study Suggests

(Cancer Research UK/Press Association) Oct 5, 2016 - Extending the gap between cervical screening tests from five to 10 years is safe for women who test negative for the human papillomavirus (HPV), according to Dutch research.
read article 

Timing of Surgery After Neoadjuvant Chemoradiation in Stage IIIA NSCLC Impacts Overall Survival

(IASLC) Oct 5, 2016 - The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.
read press release 

Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer

(NCI/Cancer Currents Blog) Oct 6, 2016 - In a clinical trial, a new immunotherapy drug called avelumab has shown promise in patients with metastatic Merkel cell carcinoma, a rare, aggressive skin cancer with few effective treatments.
read article 

Antibody Boosts PFS in Relapsed, Refractory Myeloma

(MedPage Today) Oct 5, 2016 - The addition of a monoclonal antibody to standard myeloma therapy led to significant improvement in progression-free survival (PFS) in patients with relapsed or refractory disease, results of a large randomized trial showed.
read article (free registration required) 

For Cancer Patients, Newest Treatments Force The Ultimate Decision, With No Room For Error

(STAT) Oct 6, 2016 - Late-stage cancer patients confront an array of painful decisions, but in the age of immunotherapy, patients like Rachel Lefebvre face an especially torturous one: the selection of a clinical trial.
read article 

'Uncertain' Benefits for TKIs and PD-1 Agents in NSCLC

(Medscape Medical News) Oct 6, 2016 - Tyrosine kinase inhibitors (TKIs) and programmed death-1 (PD-1) agents are increasingly used to treat patients with advanced non-small cell lung cancer, and while they can significantly prolong survival in some patients, they are not a cure and come with a hefty price tag.
read article (free registration required) 

Roche Gets Boost From FDA In Bid To Expand Uses For Actemra

(Reuters) Oct 5, 2016 - The U.S. Food and Drug Administration has granted breakthrough status to Roche's rheumatoid arthritis medication Actemra for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine.
read article 

Antitobacco Groups Sue FDA Over Graphic Labels on Cigarette Packs

(NASDAQ/Dow Jones Business News) Oct 4, 2016 - Antitobacco groups on Tuesday filed a lawsuit against the U.S. Food and Drug Administration to push the agency to try again to require graphic warning labels on cigarettes.
read article 

Pricey Hepatitis C Drugs Can Have Deadly Side-Effect for Some: FDA

( Oct 4, 2016 - Expensive hepatitis C drugs that can cure patients may come with a big risk for some: they can cause a second hepatitis virus, hepatitis B, to become active again, the Food and Drug Administration says.
read article 

QOPI Participation Leads to Improved Assessment and Management of Opioid-Associated Constipation

(ASCO in Action) Oct 4, 2016 - A new article in the Journal of Oncology Practice (JOP) used data from ASCO’s Quality Oncology Practice Initiative (QOPI®) to improve assessment and management of opioid-associated constipation (OAC).
read article 

Financial Advocates: Sharing Insights & Strategies

(ACCCBuzz) Oct 5, 2016 - Last week nearly 100 financial advocates gathered in Philadelphia, Pennsylvania, for the September 29 ACCC Financial Advocacy Network (FAN) Case-Based Workshop.
read article 

Astellas Expands Leadership in Oncology Clinical Development

( Oct 5, 2016 - Astellas today announced the appointment of Steven E. Benner, M.D., as senior vice president and Therapeutic Area Head for Oncology, and the promotion of Anne Keating, Pharm. D., to vice president of Clinical Science for Oncology, within the company's Development organization.
read article 

Renowned Lung Cancer Expert To Join NYU Langone As Chief Of Hematology And Medical Oncology

(Yahoo! News) Oct 3, 2016 - The Perlmutter Cancer Center at NYU Langone Medical Center has named noted clinician-scientist Kwok-Kin Wong, MD, PhD, as its new Chief of Hematology and Medical Oncology.
read article 

SEC Charges Former Puma Biotech Exec With $1.1 Million In Insider Trading

(STAT/Pharmalot) Sept 30, 2016 - In the latest instance of alleged insider trading in the pharmaceutical industry, a former Puma Biotechnology executive was charged with illegally making more than $1.1 million by taking advantage of confidential information about clinical trials for a cancer drug.
read article 

Celgene CEO: Myeloma And Glioblastoma Both Priorities

(BioPharma Dive) Oct 4, 2016 - Celgene’s CEO Mark Alles said during a recent R&D day that the company is expanding beyond multiple myeloma research toward brain cancer, saying the company is aggressively developing a drug, marizomib, directed against glioblastoma.
read article 

Exclusive: The Future of Immunotherapy Is Not Stopping at the Checkpoints

(Genetic Engineering News) Oct 3, 2016 - Session notes from the Second International Cancer Immunotherapy Conference.
read article (free registration required) 

Roswell Park Team Validates 10 Years of Outcomes Data for Bladder Cancer Surgeries

(RPCI) Oct 4, 2016 - Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a study based on 10 years of prospectively collected data on robot-assisted cystectomies, or surgeries to remove the bladder.
read press release 

VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

( Oct 5, 2016 – New clinical findings show that the Biodesix® VeriStrat test identifies patients with squamous cell carcinoma of the lung who are more likely to have longer progression-free and overall survival (PFS and OS) with irreversible ErbB family blocker afatinib therapy over erlotinib, a reversible EGFR tyrosine kinase inhibitor (TKI).
read article 

Billboards and Websites Push Costly Prostate Cancer Treatment With Unknown Long-Term Benefits

(STAT/Kaiser Health News) Oct 4, 2016 - Men hoping to avoid some of the dreaded side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a new procedure whose long-term effects are unknown, even though insurers, including Medicare, generally won’t pay for it.
read article 

When Push Comes to Shove—Size Matters for Particles in Our Bloodstream

(R&D Magazine) Oct 5, 2016 - Researchers at the University of Connecticut have uncovered new information about how particles behave in our bloodstream, an important advancement that could help pharmaceutical scientists develop more effective cancer drugs.
read article 

Mayo Clinic Researchers Map Prostate Cancer Relapse Using C-11 Choline PET and MRI

(Mayo Clinic) Oct 5, 2016 - A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery.
read article 

Antibody Drug Conjugates May Help Personalize Radiotherapy for Patients with Cancer

(UC San Diego Health) Oct 4, 2016 - Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
read article 

Immune-boosting Gut Microbes Can Help Chemotherapy Drugs

(Cancer Research UK/Press Association) Oct 5, 2016 - Certain microbes in the gut can help improve the effectiveness of chemotherapy drugs, according to a new study.
read article